Voronoi Inc.

Daegu-gyeongbuk Medical Innovation Foundation

Korea Institute of Science and Technology

Korea Research Institute of Bioscience and Biotechnology

Daegu Gyeongbuk Institute of Science and Technology

National Cancer Center

Samsung Life Public Welfare Foundation

Medpacto Inc.

Voronoibio Inc.

Youai Co.,ltd

Nam Doo Kim

Jung Beom Son

Hwan Geun Choi

Yi Kyung Ko

So Young Kim

Seock Yong Kang

Youn Ho Lee

Eun Hwa Ko

Sun-Hwa Lee

Eunhwa Ko

Jin-Hee Park

Seungyeon Lee

Ju Hee Kang

Dayea Kim

Sun Joo Lee

Jae Hyun Bae

Se In Kang

Sang Bum Kim

Suk Kyoon Yoon

Hee Yoon Ryu

Hee Sun Ryu

Joong-heui Cho

Eunmi Hong

Seung Min Lee

Sung Hwan Kim

Tae Bo Sim

Seung Hoon Lee

Do-Hyun Nam

Jong Bae Park

Woo Young Hur

Ho Jong Yoon

Hwan Oh Kim

Hyun Kyoung Kim

Chi Man Song

Han Na Cho

Seung Hye Choi

Sungchan Cho

Hyeon Ho Jeon

Seung Yeon Lee

Kyu-Sun Lee

Sang Hyun Min

Miri Choi

Hua Li

Seon Ah Hwang

Woo Mi Do

Kweon Yu

Young Yi Lee

Seo Hyun Jo

Joong Heui Cho

Ji Yoon Seok

Ja Wook Koo

Eun Kyong Shim

Hyang-Sook Hoe

Shinae Kim

Joongheui Cho

Sangbum Kim

Hyunkyoung Kim

Seung Yong Kim

Younho Lee

Yunho Lee

In Seob Shim

Tae-ho Jang

Seongho Hong

Sungwoo Lee

Dong Kyu Choi

Sun Hwa Lee

Tae-Ho Jang

Tae Bo Shim

Jaeyoung Song

Hong Ryul Jung

Seung Su Kim

Dong Keun Hwang

Joong-Heui Cho

Da Eun Kim

The present invention relates to an N-containing heteroaryl derivative and a pharmaceutical composition comprising same as an active ingredient for the prevention or treatment of cancer. The derivative exhibits high inhibitory activity against various protein kinases, particularly excellent ret proto-oncogene (RET) enzyme inhibitory ability, and has an excellent effect of inhibiting the proliferation of medullary thyroid cancer cells and lung cancer cells, which express RET fusion genes, and thus the derivative can be effectively used in the treatment of cancer, for example, medullary thyroid cancer or lung cancer, and particularly, can be effectively used in the treatment of cancer in which RET fusion genes are expressed.

N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer

The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.

Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component

The present disclosure relates to a heteroaryl derivative and uses thereof. The heteroaryl derivative of the present disclosure exhibits excellent inhibitory activity against EGFR and/or HER2, and thus may be usefully employed as a therapeutic agent for EGFR- and/or HER2-related diseases.

Heteroaryl derivative compounds, and uses thereof

The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases. 

Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease

The present invention relates to a pyrrolo-pyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.

Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases

The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. Also, the novel imidazopyridine derivative according to the present invention, the stereoisomer thereof, and the pharmaceutically acceptable salt thereof can effectively inhibit Src and Fyn, thereby being useful as a pharmaceutical composition for preventing or treating the Src and Fyn related diseases, and in particular, have been confirmed to be useful in diabetic nephropathy in animal model experiments. Therefore, the compound of the present invention can be effective as a pharmaceutical composition containing the same as an active ingredient for preventing or treating diabetic nephropathy.

Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer

The present invention relates to a novel 2,3,5-substituted thiophene compound having inhibitory activity against kinases, an anticancer agent including the compound as an active ingredient, and a method for preparing the compound.

2,3,5-substituted thiophene compound as protein kinase inhibitor

A novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition with an inhibitory activity against Raf kinase, containing the same as an active ingredient are provided. The purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of the present invention effectively regulates the activity of B-Raf kinase, and thus may be useful for preventing or treating cancers induced by the over-activation of Raf kinase, especially various melanoma, colorectal cancer, prostate cancer, thyroid cancer, ovarian cancer and the like.

Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient

Growing community of inventors

Daegu, South Korea

Nam Doo Kim